Phospholipase A2 Group IVB (PLA2G4B) is a member of the phospholipase A2 enzyme family, which hydrolyzes phospholipids to release free fatty acids, including arachidonic acid, a precursor for inflammatory mediators. PLA2G4B, also known as cytosolic phospholipase A2 beta (cPLA2β), shares structural homology with the well-studied PLA2G4A (cPLA2α) but exhibits distinct tissue expression patterns and regulatory mechanisms. It is implicated in membrane remodeling, lipid signaling, and inflammatory responses, though its specific biological roles remain less characterized compared to other PLA2 isoforms.
Antibodies targeting PLA2G4B are critical tools for investigating its expression, localization, and function in physiological and pathological contexts. These antibodies are commonly validated for applications such as Western blotting, immunohistochemistry, and immunofluorescence. Research suggests PLA2G4B may contribute to diseases involving lipid dysregulation, such as cancer, metabolic disorders, or neurodegenerative conditions, though conclusive evidence is limited.
Commercial PLA2G4B antibodies are typically raised against unique peptide sequences or recombinant protein fragments to ensure specificity. Researchers must verify cross-reactivity with homologous isoforms, particularly PLA2G4A, to avoid misinterpretation. Recent studies highlight its potential as a biomarker or therapeutic target, driving demand for reliable antibodies to advance mechanistic insights. However, the functional ambiguity of PLA2G4B underscores the need for further exploration using antibody-based methodologies.